Microdosing Tirzepatide: What the Data Says

Microdosing means weekly doses below the lowest clinical label (under 2.5 mg). Researchers use it for tolerance, side-effect minimisation, or long-term maintenance. Here is what the published data and field reports actually say.

Common microdose protocols

  • 1.25 mg weekly — the most common microdose. Half the standard starting dose.
  • 2.5 mg every two weeks — for maintenance after weight goals are met.
  • 0.5 mg twice weekly — splits the dose for gentler PK curves.

When microdosing helps

  • Sensitive GI response to standard 2.5 mg
  • Maintenance after a successful weight-loss research phase
  • Cost-stretching while staying in protocol
  • Older or smaller-bodyweight subjects

Caveats

Below 1 mg weekly, the appetite-suppression effect drops off sharply. Microdosing is not a substitute for a proper titration — see the full schedule.

Frequently asked questions

Will microdosing maintain weight loss?

For most researchers, yes. Maintenance doses of 2.5 mg every 7–14 days tend to hold results.

Is microdosing safer?

It has lower side-effect rates but no long-term safety advantage has been proven.

Do I need a smaller syringe?

No — a standard U-100 insulin syringe handles microdoses with the right dilution.

This guide is provided for informational purposes by Next Day Pharma. All peptides supplied are FOR RECONSTITUTION. Always consult a qualified healthcare professional before use.